01:05 PM EST, 12/11/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our 12-month target price by $22 to $342, valuing the shares at 13x our 2026 operating EPS estimate of $26.15 and at 12.1x our 2027 EPS estimate of $28.20, versus a disparate peer average of 13x (including some slower-growing firms that lack CB's market presence and balance-sheet strength and some faster-growing firms) and its three-year average forward multiple of 12.3x. We think CB's ability to leverage selective pricing strength will provide its shares with a catalyst. We are encouraged that claim costs have moderated despite higher Q1 catastrophes. We view CB as a top-tier underwriter and believe the combination of this strength with a still-adequate pricing environment and an expected stable demand for coverage provides the shares with a catalyst. We also view Berkshire Hathaway's acquisition of an 8% equity stake in CB as a positive for the shares.